Articles tagged with Malaria
A new GM mosquito sexing technique allows for the quick identification of males, paving the way for releasing sterile males to control mosquito populations. This could lead to a significant reduction in malaria cases and population growth.
In KwaZulu-Natal, South Africa, hospital admissions for malaria dropped by 89% after introducing an antimalarial combination called artemether-lumefantrine (AL) and improving mosquito control with DDT. The province also saw a significant decline in outpatient cases and malaria-related deaths.
Researchers used microscopy and fluorescent tags to study malaria parasite release from infected red blood cells. They found that membranes fold into small vesicles allowing parasites to infect neighboring cells through pressure build-up.
The study reveals the malaria parasite's release mechanism from infected red blood cells, contradicting previous theories. The findings provide new insights into the disease and its potential targets for treatment.
The UN's Deputy Secretary General orders delay on measurement of life-saving goals, citing concerns over 'distracting' from desired results. This decision diverts attention from a key problem: concrete trends toward helping people in extreme poverty often lack verification.
Researchers have identified a promising protein, AMA1, as a potential component for a malaria vaccine. The protein is produced in two critical stages of the parasite life cycle and has slight structure variations called polymorphisms that impact its development.
An international team of scientists has discovered the gene PfRh4 that allows the malaria parasite to switch between potential invasion points on red blood cells. The inactivation of this single protein could block multiple entry points currently open to the parasite, paving the way for new anti-malarial vaccine designs.
A new trial has found that artesunate is more effective and has fewer side effects than the standard treatment of quinine in treating severe malaria. The study involved over 1,400 patients from four countries and showed a significant reduction in mortality rates with artesunate treatment.
A randomized controlled trial found that parenteral artesunate reduced mortality from severe malaria by 15% compared to quinine, while also being safer and simpler to administer. The study calls for quality-assured, affordable artesunate to be made widely available in malaria-endemic areas.
Researchers develop new method to detect sequestered malaria parasites in red blood cells. The study found that patients with severe malaria have six times higher parasite burden than those without severe symptoms.
Researchers discovered a new compound, LMP-420, that potently reduces activation of endothelial cells and inflammation in cerebral malaria. This finding offers a promising avenue for treating the condition, which has a high fatality rate despite existing treatments.
A four-year trial in Papua New Guinea is investigating the use of Fansidar as a preventative measure against malaria in children under five and pregnant women. The study suggests that giving just one tablet can reduce the impact of subsequent malaria infections by up to 50%, saving thousands of lives annually.
Researchers found that mosquitoes were significantly more attracted to children with infectious stages of malaria, whereas treatment with antimalarial drugs showed no difference in attractiveness.
Researchers have discovered the molecular mechanism of malaria parasite invasion into red blood cells, revealing a key protein-protein interaction known as the RII handshake. This finding suggests that blocking this interaction could be an effective strategy for preventing and treating malaria.
Researchers found cheaper combination of drugs equally effective as artemisinin-based treatment in preventing recurrent malarial infections. In sites with high transmission rates, the cheaper combination worked better, highlighting cost as a major concern.
Researchers are developing genetically altered malaria parasites to stimulate immunity against the disease. The goal is to boost the immune system in a similar way to how the altered polio bacteria triggers immunity against polio.
Eight Melbourne scientists, including six from WEHI, have been awarded five-year grants to tackle infectious and parasitic diseases like malaria. The $23.3 million international program aims to understand disease mechanisms, identify new drug targets, and develop vaccines.
Menzies Research Institute director Professor Foote awarded $17.5 million US grant to expand genetic research program on malaria. He will investigate how humans' immune systems fight malaria by infecting lab mice with rare genetic mutations.
The Howard Hughes Medical Institute (HHMI) has selected 42 biomedical scientists from around the world to receive international research grants. These awardees will contribute to advancing global health and medical innovation through their research projects, with a focus on infectious diseases, parasitology, and immunology.
Researchers at Vanderbilt University aim to develop powerful chemical repellents and attractants to interfere with malaria mosquitoes' ability to find human targets. The project uses genetic engineering, molecular biology, and field-based studies to establish an effective strategy for reducing malaria spread.
A Yale University research project aims to reduce malaria transmission by identifying effective odor cues that attract or repel mosquitoes. The team will test these odors in simulated natural situations and eventually distribute them to African villages for practical tests.
Researchers found that abnormal distribution of PfEMP-1 protein on red blood cells containing hemoglobin C impairs malaria parasites' ability to cause disease symptoms. This may explain why individuals with at least one gene for hemoglobin C are less prone to severe malaria.
Researchers have found that carrying the sickle cell gene provides partial protection against malaria, increasing to 60% in childhood before declining. The study suggests an immune component to this protection and may offer insights into developing an effective vaccine.
Researchers developed disease models using yeast to test resistance to atovaquone and created a practical tool to design new anti-malarial drugs. This study provides the first quantitative explanation for malaria's drug resistance, enabling the development of new treatments within 3-5 years.
A randomized trial in Uganda found a six-dose regimen of co-artemether significantly reduced gametocyte levels and mosquito infectivity. However, limitations include patient compliance and absorption issues.
A malaria vaccine, RTS, S/AS02, has shown substantial protection in trials, with 30% and 58% effectiveness rates. However, an efficacious vaccine is not yet available for widespread use due to funding and organizational challenges. Experts predict a decade-long timeline for the development of a viable vaccine.
A recent study has found that a combination of artemether-lumefantrine to be highly effective in treating malaria in children aged 4-59 months. The treatment showed an impressive success rate of over 96% in a Tanzanian trial, paving the way for its potential use as a substitute for failing therapies in African countries.
The Roll Back Malaria partnership, which includes WHO, UNICEF, and the World Bank, has failed to achieve its aims of reducing malaria mortality. Despite a seven-year initiative, malaria rates have increased, making it unlikely that the 2010 target to halve deaths will be met.
A new study found that administering anti-malarial drugs to infants just three times can reduce the incidence of malaria by 59% in the first year of life. The treatment, known as intermittent preventative malarial treatment (IPT), was also shown to provide long-term protection against malaria episodes in children up to two years old.
Pneumonia, diarrhea, and undernutrition are major contributors to child deaths worldwide. The new estimates also show that nearly half of all child deaths occur within the first 28 days of life, primarily due to preterm delivery, sepsis, or pneumonia.
In West Papua, patients often initially choose indigenous treatments for illnesses, but switch to biomedical options if they don't work. After initial failure, individuals focus on finding the cause of their illness, attributing it to factors like ancestral spirits, magic, or biological responses.
A study found that US Army personnel deployed to eastern Afghanistan between June and September 2002 had a significant risk of malaria infection upon return. The researchers identified 38 patients infected with malaria, resulting in an attack rate of 52.4 cases per 1,000 soldiers.
Scientists have identified key genes and gene regulation mechanisms in malaria parasites, which could lead to the development of new vaccines. The study's findings may help researchers understand when different genes switch on and off as the parasite metamorphoses through its complex life cycle.
Scientists at Northwestern University have identified a signal on exported parasite proteins that enables the malaria parasite to target red blood cells. This discovery provides a new understanding of the complex mechanisms underlying malaria infection and offers promising leads for developing new treatments.
Researchers identified a subset of proteins vital to malaria parasite's survival in host red blood cells and a unique mechanism for protein export. This discovery allows for focus on key proteins for developing antimalarial drugs.
Researchers found that HIV-1 protease inhibitors, such as saquinavir and ritonavir, effectively inhibit P. falciparum growth and demonstrate anti-malarial activity. The study builds on previous findings of antiretroviral agents reducing parasite adhesion to endothelial surfaces.
Researchers have discovered VAR2CSA, a protein that enables malaria parasites to infect the placenta during pregnancy. Women with high levels of antibodies against this protein experience fewer complications and give birth to healthier babies.
A new malaria vaccine trial found only 10% vaccine efficacy in Gambian adults, but the DNA/MVA vaccine group showed a significantly stronger immune response than the rabies vaccine group. The researchers are planning further trials to address this issue and develop a more effective malaria vaccine.
Researchers develop mathematical model to predict mosquito-borne infection risk, finding that peak biting rates occur near breeding sites and highest human density. The proportion of infectious mosquitoes peaks where older populations are found, leading to surprising predictions about risk hotspots.
Researchers found that none of the 35 children with moderate-to-severe malaria in Gabon were severely dehydrated. This challenges the long-held view that dehydration is a major contributor to fatal cases of malaria.
A malaria vaccine trial has shown encouraging phase II results, demonstrating a 30% reduction in clinical episodes of malaria among young children. The RTS,S/AS02A vaccine has also shown effectiveness in preventing subsequent new infections and severe malaria cases.
A new report highlights the potential of biotechnologies in improving health in developing countries. The report proposes a global institute to share and promote the benefits of genomic sciences, aiming to save tens of millions of lives per year.
A study of US travelers who died from malaria between 1963 and 2001 found that most deaths were preventable with proper medication and medical care. The researchers call for better education and resources for travelers and healthcare providers to reduce malaria-related deaths.
A study by the Centers for Disease Control and Prevention (CDC) found that most US malaria deaths are preventable, with human error and inadequate medical care contributing to nearly two-thirds of cases. The CDC has expanded resources available to provide critical information on prevention and treatment of malaria.
A recent study has identified previously unknown mutations in the pfrct gene as key players in Plasmodium falciparum's resistance to halofantrine and amantadine. These mutations may also restore sensitivity to chloroquine, a widely used antimalarial drug. The findings suggest a new approach to combating chloroquine-resistant malaria.
Researchers at Johns Hopkins University have designed dual-action drugs based on an ancient folk remedy, which shows promising results in fighting malaria and prostate cancer. The new compounds outperform current treatments in rodent models, with some being more effective and safer than existing medications.
A new study found that undernutrition significantly contributes to the global malaria burden, particularly in children less than 5 years old. Well-nourished children are better equipped to fight and survive malaria infection.
Scientists warn of international spread of antimalarial drug resistance, tracing mutations to South East Asia and recommending screening of passengers from affected regions. Artemisinin-based combination therapy may help slow the spread, but a coordinated global response is needed.
A study of 326 children with severe malaria found that 61% had retinopathy, which was associated with higher death rates and prolonged coma. The researchers suggest that retinal signs may be related to cerebral pathophysiology in childhood CM.
A laboratory-based study suggests that inadequate vaccines could lead to the emergence of more virulent malaria strains, potentially making them more dangerous to non-immunized populations. The research found that immunity accelerates the evolution of virulence in malaria parasites, even after mosquito transmission.
A new study reveals that improved nutrition can prevent over half of the world's child deaths every year. Researchers found that even mild undernutrition increases a child's risk of dying from diarrhea, pneumonia, malaria, and measles by two-fold. Investing in child nutrition interventions could save millions of young lives.
The partnership aims to enhance Peruvian research capacity in biomedical research, including lab-based and fieldwork. The project will cover research ethics, health economics, and train local researchers, physicians, biologists, nurses, and students.
A study found that rectal artesunate significantly reduced parasite concentrations by over one-third in both children and adults. Early administration of this treatment may help reduce malaria-related morbidity and mortality, particularly in rural communities with limited healthcare access.
Researchers identified a plant-like enzyme, CDPK4, essential for malaria parasite transmission to mosquitoes. The findings provide a promising new target for developing safe and effective anti-malarial drugs.
A randomized double-blind cross-over study involving 22 healthy volunteers found that Malarone(TM) had no significant effect on vigilance, alertness, or quality of sleep. The results support previous studies showing Malarone(TM) has no impact under normal pressure conditions.
Researchers have identified a new protein target for a universal childhood malaria vaccine, which causes infected red blood cells to stick inside blood vessels. This protein is expressed on the surface of red blood cells during severe childhood malaria but not during adult infections, making it an ideal candidate for vaccination.
Researchers at UC Davis suggest using transposons to introduce genes that block malaria in mosquitoes, which could spread through the population via natural selection and eventually eliminate malaria transmission.
Researchers have discovered two mosquito proteins, TEP1 and LRIM1, that kill the malaria parasite. Eliminating these proteins could block the parasite-mosquito cycle, potentially decreasing malaria prevalence.
The new assay uses fluorochrome binding to detect malaria parasites in cell culture, providing a safer and more cost-effective alternative to current methods. This breakthrough has the potential to drastically reduce the price tag for drug discovery and promote research into tropical parasitic diseases.
The Lancet article reveals that inadequate funding for effective treatments like ACT is contributing to the increase in global childhood malaria deaths. Inappropriate drug distribution by WHO and GFATM is being criticized for wasting international aid money and potentially killing patients.